-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of CDE showed that Nanjing Chia Tai Tianqing had been accepted for copying regorafenib tablets of 4 types of applications
.
According to data from Meinenet, the global sales of Regorafenib in 2020 will reach 475 million euros (approximately US$556 million), and the total sales of Regorafenib in the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities exceed 600 million yuan.
, The domestic regorafenib tablet manufacturer is only the original Bayer one
.
In April of this year, Yangtze River Pharmaceutical Group's Regorafenib tablets submitted an application for listing and is under review and approval
.
.
According to data from Meinenet, the global sales of Regorafenib in 2020 will reach 475 million euros (approximately US$556 million), and the total sales of Regorafenib in the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities exceed 600 million yuan.
, The domestic regorafenib tablet manufacturer is only the original Bayer one
.
In April of this year, Yangtze River Pharmaceutical Group's Regorafenib tablets submitted an application for listing and is under review and approval
.
Data show that regorafenib can block a variety of enzymes that promote tumor growth, and inhibit tumor formation, angiogenesis and tumor microenvironment formation through multiple kinases acting on tumor cells, endothelial cells and peripheral cells
.
.
Global sales of rigorfenib in recent years (unit: million euros)
Source: Mynet.
com's sales database of multinational listed companies
com's sales database of multinational listed companies
According to data from Mi Nei.
com, the global sales of Rigofinil have steadily increased in recent years, reaching 475 million euros (approximately US$556 million) in 2020
.
In 2020, the total sales of Regofinil in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will exceed 600 million yuan.
Among them, in China The terminal growth rate of public medical institutions is the fastest, exceeding 50%
.
com, the global sales of Rigofinil have steadily increased in recent years, reaching 475 million euros (approximately US$556 million) in 2020
.
In 2020, the total sales of Regofinil in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will exceed 600 million yuan.
Among them, in China The terminal growth rate of public medical institutions is the fastest, exceeding 50%
.
Source: One-click search on Mi Nei.
com
com
At present, the domestic manufacturer of Rigofinil tablets is only the original Bayer one
.
In April of this year, Yangtze River Pharmaceutical Group's Regorafenib tablets submitted a listing application in 4 types of imitations, and they are under review and approval
.
.
In April of this year, Yangtze River Pharmaceutical Group's Regorafenib tablets submitted a listing application in 4 types of imitations, and they are under review and approval
.
Nanjing Chia Tai Tianqing has been approved for listing and production of products under review since 2021
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
A few days ago, Nanjing Chia Tai Tianqing's sofosbuvir tablets and lenvatinib mesylate capsules were approved.
Since the beginning of this year, Nanjing Chia Tai Tianqing has approved 6 products for the market
.
In addition, three products including Tedizolamide Phosphate Tablets and Tedizolamide Phosphate for Injection have been submitted for production under review and approval
.
Since the beginning of this year, Nanjing Chia Tai Tianqing has approved 6 products for the market
.
In addition, three products including Tedizolamide Phosphate Tablets and Tedizolamide Phosphate for Injection have been submitted for production under review and approval
.
Source: CDE official website, Minet database
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
The review data statistics are as of August 20, if there are any errors or omissions, please correct me
.
.
A few days ago, the official website of CDE showed that Nanjing Chia Tai Tianqing had been accepted for copying regorafenib tablets of 4 types of applications
.
According to data from Meinenet, the global sales of Regorafenib in 2020 will reach 475 million euros (approximately US$556 million), and the total sales of Regorafenib in the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities exceed 600 million yuan.
, The domestic regorafenib tablet manufacturer is only the original Bayer one
.
In April of this year, Yangtze River Pharmaceutical Group's Regorafenib tablets submitted an application for listing and is under review and approval
.
.
According to data from Meinenet, the global sales of Regorafenib in 2020 will reach 475 million euros (approximately US$556 million), and the total sales of Regorafenib in the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities exceed 600 million yuan.
, The domestic regorafenib tablet manufacturer is only the original Bayer one
.
In April of this year, Yangtze River Pharmaceutical Group's Regorafenib tablets submitted an application for listing and is under review and approval
.
Data show that regorafenib can block a variety of enzymes that promote tumor growth, and inhibit tumor formation, angiogenesis and tumor microenvironment formation through multiple kinases acting on tumor cells, endothelial cells and peripheral cells
.
.
Global sales of rigorfenib in recent years (unit: million euros)
Source: Mynet.
com's sales database of multinational listed companies
com's sales database of multinational listed companies
According to data from Mi Nei.
com, the global sales of Rigofinil have steadily increased in recent years, reaching 475 million euros (approximately US$556 million) in 2020
.
In 2020, the total sales of Regofinil in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will exceed 600 million yuan.
Among them, in China The terminal growth rate of public medical institutions is the fastest, exceeding 50%
.
com, the global sales of Rigofinil have steadily increased in recent years, reaching 475 million euros (approximately US$556 million) in 2020
.
In 2020, the total sales of Regofinil in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will exceed 600 million yuan.
Among them, in China The terminal growth rate of public medical institutions is the fastest, exceeding 50%
.
Source: One-click search on Mi Nei.
com
com
At present, the domestic manufacturer of Rigofinil tablets is only the original Bayer one
.
In April of this year, Yangtze River Pharmaceutical Group's Regorafenib tablets submitted a listing application in 4 types of imitations, and they are under review and approval
.
.
In April of this year, Yangtze River Pharmaceutical Group's Regorafenib tablets submitted a listing application in 4 types of imitations, and they are under review and approval
.
Nanjing Chia Tai Tianqing has been approved for listing and production of products under review since 2021
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
A few days ago, Nanjing Chia Tai Tianqing's sofosbuvir tablets and lenvatinib mesylate capsules were approved.
Since the beginning of this year, Nanjing Chia Tai Tianqing has approved 6 products for the market
.
In addition, three products including Tedizolamide Phosphate Tablets and Tedizolamide Phosphate for Injection have been submitted for production under review and approval
.
Since the beginning of this year, Nanjing Chia Tai Tianqing has approved 6 products for the market
.
In addition, three products including Tedizolamide Phosphate Tablets and Tedizolamide Phosphate for Injection have been submitted for production under review and approval
.
Source: CDE official website, Minet database
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
The review data statistics are as of August 20, if there are any errors or omissions, please correct me
.
.
A few days ago, the official website of CDE showed that Nanjing Chia Tai Tianqing had been accepted for copying regorafenib tablets of 4 types of applications
.
According to data from Meinenet, the global sales of Regorafenib in 2020 will reach 475 million euros (approximately US$556 million), and the total sales of Regorafenib in the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities exceed 600 million yuan.
, The domestic regorafenib tablet manufacturer is only the original Bayer one
.
In April of this year, Yangtze River Pharmaceutical Group's Regorafenib tablets submitted an application for listing and is under review and approval
.
.
According to data from Meinenet, the global sales of Regorafenib in 2020 will reach 475 million euros (approximately US$556 million), and the total sales of Regorafenib in the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities exceed 600 million yuan.
, The domestic regorafenib tablet manufacturer is only the original Bayer one
.
In April of this year, Yangtze River Pharmaceutical Group's Regorafenib tablets submitted an application for listing and is under review and approval
.
Data show that regorafenib can block a variety of enzymes that promote tumor growth, and inhibit tumor formation, angiogenesis and tumor microenvironment formation through multiple kinases acting on tumor cells, endothelial cells and peripheral cells
.
Tumor tumor tumor.
Global sales of rigorfenib in recent years (unit: million euros)
Source: Mynet.
com's sales database of multinational listed companies
com's sales database of multinational listed companies
According to data from Mi Nei.
com, the global sales of Rigofinil have steadily increased in recent years, reaching 475 million euros (approximately US$556 million) in 2020
.
In 2020, the total sales of Regofinil in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will exceed 600 million yuan.
Among them, in China The terminal growth rate of public medical institutions is the fastest, exceeding 50%
.
Hospital hospital hospital pharmacy pharmacy pharmacycom, the global sales of Rigofinil have steadily increased in recent years, reaching 475 million euros (approximately US$556 million) in 2020
.
In 2020, the total sales of Regofinil in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will exceed 600 million yuan.
Among them, in China The terminal growth rate of public medical institutions is the fastest, exceeding 50%
.
Source: One-click search on Mi Nei.
com
com
At present, the domestic manufacturer of Rigofinil tablets is only the original Bayer one
.
In April of this year, Yangtze River Pharmaceutical Group's Regorafenib tablets submitted a listing application in 4 types of imitations, and they are under review and approval
.
.
In April of this year, Yangtze River Pharmaceutical Group's Regorafenib tablets submitted a listing application in 4 types of imitations, and they are under review and approval
.
Nanjing Chia Tai Tianqing has been approved for listing and production of products under review since 2021
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
A few days ago, Nanjing Chia Tai Tianqing's sofosbuvir tablets and lenvatinib mesylate capsules were approved.
Since the beginning of this year, Nanjing Chia Tai Tianqing has approved 6 products for the market
.
In addition, three products including Tedizolamide Phosphate Tablets and Tedizolamide Phosphate for Injection have been submitted for production under review and approval
.
Since the beginning of this year, Nanjing Chia Tai Tianqing has approved 6 products for the market
.
In addition, three products including Tedizolamide Phosphate Tablets and Tedizolamide Phosphate for Injection have been submitted for production under review and approval
.
Source: CDE official website, Minet database
Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
The review data statistics are as of August 20, if there are any errors or omissions, please correct me
.
.
